33 results about "Myopathy" patented technology

The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods of treating neuromuscular inflammatory indications, such as Immune-Mediated Necrotizing Myopathy.

The present invention relates to chemical compounds useful as inhibitors of class II phosphoinositide 3-kinase (PI3K) signaling. The invention further relates to the medical use of inhibitors of class II phosphoinositide 3-kinase (PI3K) signaling in the treatment of medical conditions associated with defective and / or pathological class II phosphoinositide 3-kinase (PI3K) signaling, such as stroke, cardiovascular diseases associated with endothelial cell dysfunction, cancer, cancerometastasis, myopathy and diabetes.

This invention provides compounds for the treatment, prevention, or suppression of various pathological conditions (such as proliferative disorders like cancer, β-globin disorders, fibrosis, pain, neurodegenerative diseases, Prader-Willi syndrome, malaria, viral infections, myopathy, and autism) by inhibiting G9a. [Solution] The following general formula (I) TIFF2026062914000401.tif2449 A compound represented by or a pharmacoposly acceptable salt thereof is provided.

We provide gene therapy for the treatment of muscular dystrophy, including but not limited to Duchenne muscular dystrophy (DMD). [Solution] This disclosure provides a recombinant adeno-associated virus (rAAV) comprising a nucleic acid molecule that delivers a nucleic acid encoding a U7-based snRNA, which is a nucleic acid that induces exon skipping for use in the treatment of muscular dystrophy, including but not limited to DMD, resulting from any mutation suitable for skipping exon 44 of the DMD gene (DMD exon 44), including but not limited to mutations involved in or affecting DMD exon 44.

The present disclosure is directed to methods of treatment, including treatment of a myopathy by administering to a subject in need thereof an elastase inhibitor in combination with a glucocorticoid. The present disclosure is also directed to pharmaceutical compositions that include an elastase inhibitor that can be used in such treatment.

The application provides a kind of medicine composition for treating muscle and bone disease and its application, belong to medical technology field.The medicine composition includes the following weight parts components: compound angelica injection 5-10 parts, kadsura injection 5-10 parts, wild medlar injection 5-10 parts, methylcobalamin injection 5-10 parts;It can also be selectively added vitamin B1 injection, vitamin B12 injection, yellow Chinese wax injection or bone peptide injection.The composition of the application is administered by acupoint injection or intramuscular injection, utilizes the synergistic effect of multiple traditional Chinese medicine injection and western medicine injection, reaches the comprehensive treatment effect of promoting blood circulation to remove blood stasis, dispelling wind to stop pain, nerve nutrition.Clinical experiments show that the application has significant effect on lumbar disc herniation, cervical spondylosis, shoulder periarthritis, knee osteoarthritis, femoral head necrosis, osteoporosis and the like, and the total effective rate is more than 95%, with fast effect, low recurrence rate, and no hormone-related side effects, suitable for patients of all ages.

The invention belongs to the technical field of biology, and discloses an application of sodium crotonate in the aspect of regulating and controlling muscle development, and an application of sodium crotonate in serving as and / or preparing a medicine for regulating and controlling muscle development. The invention discloses the dual effects of sodium crotonate in skeletal muscle development regulation for the first time, and provides a new potential target and a chemical intervention approach for muscle regeneration and treatment of atrophic myopathy and metabolic muscle diseases. On the other hand, the sodium crotonate is a low-toxicity metabolite, can be used in conventional solution preparation and injection modes, and has application prospects.

The application discloses a method for constructing a myopathy animal model, the constructed model and application of the model. The application also provides application of a reagent for knocking out or mutating a PRR14 gene or inhibiting expression of the gene in preparation of a myopathy animal model product. Specifically, compared with normal mice, total muscle mass, grip level and muscle endurance of the mice with muscle tissue-specific knockout of the PRR14 gene are all significantly reduced, the animal model provided by the application has typical characteristics of myopathy, can well simulate occurrence and development of myopathy in vivo, is an ideal animal model for basic and clinical application research of myopathy, and can be well applied to screening of drugs for treating myopathy.

The application provides a method for constructing a mouse model of mitochondrial myopathy with a Lars2 gene deletion and application thereof, a first Lars2 flox / flox mouse is obtained by crossing an Acta1 ER‑Cre mouse with an Acta1 ER‑Cre -Lars2 flox / flox mouse; in the second step, the above mouse reaches 4 weeks of age, and tamoxifen 70-80 mg / kg is used for continuous intraperitoneal injection for 5 days; in the third step, 4 weeks later, tamoxifen 45-55 mg / kg is used for continuous intraperitoneal injection for 5 days; in the fourth step, the Acta1 ER‑Cre -Lars2 flox / flox mouse reaches 12-13 weeks of age, and skeletal muscle Lars2 protein deletion occurs, and skeletal muscle atrophy occurs obviously at 16 weeks of age, thereby obtaining a mouse model of mitochondrial myopathy with a Lars2 gene deletion.

The invention provides a myopathy progress prediction method and device based on a spatio-temporal topology network, and the method comprises the steps: carrying out the image segmentation and quantification of muscle biopsy sections of a patient at a plurality of time points, constructing a static pathological topology network with a single muscle fiber as a node and a spatial adjacency relation as an edge, and enabling the node to comprise the multi-dimensional features of subtypes, forms, textures, cell nucleuses and the like; and forming time-space diagram data according to a time sequence. The data are input into a pre-trained space-time diagram neural network, a space coding layer aggregates neighborhood information through a diagram convolutional network to capture space interaction, a time coding layer learns a time sequence evolution rule through a recurrent neural network, and a decoding layer predicts a network state of a next time point. Pathological network sequences of multiple time points in the future are generated through iterative prediction, then key indexes are extracted to draw a quantitative prediction curve, a visual pathology heat map is generated, crossing from static pathology to dynamic progress is achieved, and an objective and accurate myopathy prognosis evaluation tool is provided for clinic.

The present invention relates to a composition comprising sialyloligosaccharide and N-acetylmannosamine for the treatment of GNE myopathy, and a method of using same. Despite ManNac exhibiting non-significant sialylation activity in GNE knockdown (GNE KD) C2C12 skeletal muscle cells, it was confirmed that co-administration of ManNac and sialyloligosaccharide promotes sialylation more effectively than single administration, thereby exhibiting an excellent synergistic effect. Such effects have also been confirmed in an animal model of GNE myopathy, and thus the combined therapy of ManNAc and sialyloligosaccharide of the present invention is expected to be advantageously employed as a novel therapeutic approach capable of overcoming hyposialylation caused by sialic acid deficiency in GNE myopathy.

The application belongs to the technical field of biological medicine, and particularly relates to application of a reagent for detecting anti-DLAT autoantibody in preparation of a product for detecting and / or diagnosing immune-mediated necrotizing myopathy. Experiments prove that DLAT can be used as a recognition antigen of an immune-mediated necrotizing myopathy related autoantibody, DLAT is a target point of the immune-mediated necrotizing myopathy autoantibody, the reactivity of the anti-DLAT autoantibody with the related antigen in dermatomyositis is 0%, the reactivity of the anti-DLAT autoantibody with other antigens HMGCR and SRP of the immune-mediated necrotizing myopathy is 0%, the anti-DLAT autoantibody is a new biological marker of the immune-mediated necrotizing myopathy, and the immune-mediated necrotizing myopathy can be detected and / or diagnosed.

A method of treating idiopathic inflammatory myopathy in an individual is described. The method involves administering an effective amount of umbilical lining-derived stem cells to the individual. The method may involve reducing or tapering steroid usage in individual afflicted with idiopathic inflammatory myopathy. The method may involve administering a single dose of the umbilical lining-derived stem cells, or administering multiple doses of the umbilical lining-derived stem cells over a defined period of time.

Adult form glycogen storage disease type III (GSD III) is an orphan neuromuscular disorder caused by a deficiency of glycogen debranching enzyme. Long-term complications include progressive liver fibrosis, hepatic failure, and end-stage liver cirrhosis, and progressive muscle myopathy. Presently, there are no clinically approved therapies or cures for GSD III. Disclosed herein are compositions for and methods of treating and / or preventing GSD III disease progression.

The present disclosure provides methods of detecting and treating idiopathic inflammatory myopathies (IIM). It was surprisingly discovered that autoantibodies against dysferlin are common in subjects having IIM patients and that the levels of dysferlin antibodies are linked with the severity and the progression of the disease. In some embodiments, it includes a method of treating idiopathic IIM in a subject, comprising, obtaining a sample from the subject, measuring the level of one or more dysferlin autoantibodies in the subject, and administering a therapeutically effective dose of an agent that inhibits one or more dysferlin autoantibodies, when an increase of IIM was measured in a subject.

The invention relates to the technical field of biological breeding, in particular to application of BMP6 protein or a coding gene thereof to regulation and control of myogenic differentiation of poultry skeletal muscle satellite cells. The invention finds that the BMP6 gene is a key factor for regulating and controlling the senescence of the muscle-derived satellite cells and inducing the cells to be converted from an activated state to a resting state through the research of an snRNA-seq combined in-vivo and in-vitro method, and proves that the knock-down of the BMP6 can promote the activation and myogenic differentiation of the skeletal muscle satellite cells. The invention provides a new way for improving the meat production performance of poultry, breeding an improved variety and preventing and treating related myopathy.

The technology as disclosed herein includes systems, methods, and compositions for detection of disease in a subject using spectroscopy and includes more effective detection of muscular myopathies in commercially farmed animals using infrared spectroscopy, and includes detection of Wooden Breast, White Striping, and / or Spaghetti Meat in broiler chickens utilizing near infrared spectroscopy. Implementations of the systems, methods, and compositions provided herein include and / or utilize and / or provide for detection of Wooden Breast, White Striping, and / or Spaghetti Meat in broiler chickens utilizing near infrared spectroscopy of breast area of live birds for prediction of taurine levels in the muscle.

The present disclosure provides, inter alia, compositions and methods for treating premature aging of muscle stem cells to combat myopathy by targeting Cdkn2a.

The technology as disclosed herein includes systems, methods, and compositions for detection of disease in a subject using spectroscopy and includes more effective detection of muscular myopathies in commercially farmed animals using infrared spectroscopy, and includes detection of Wooden Breast, White Striping, and / or Spaghetti Meat in broiler chickens utilizing near infrared spectroscopy. Implementations of the systems, methods, and compositions provided herein include and / or utilize and / or provide for detection of Wooden Breast, White Striping, and / or Spaghetti Meat in broiler chickens utilizing near infrared spectroscopy of breast area of live birds for prediction of taurine levels in the muscle.

The present invention relates to methods and compositions for treating muscle diseases and disorders. The invention provides methods for treating muscle myopathies, including muscular dystrophy and cardiomyopathy, by administering stable, long-acting therapeutic agents for vasoactive intestinal peptides. These agents include one or more elastin-like peptides and can be administered at low doses.

Compositions consist essentially of trigonelline or consist of trigonelline. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to a mammal to treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The mitochondria-related disease or condition is selected from the group consisting of deleterious effects of aging, stress (e.g., oxidative stress), obesity, overweight, reduced metabolic rate, metabolic syndrome, diabetes mellitus, complications from diabetes, hyperlipidemia, neurodegenerative disease, cognitive disorder, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal death or dysfunction, chronic kidney disease, kidney failure, trauma, infection, cancer, hearing loss, macular degeneration, myopathies and dystrophies, and combinations thereof.

A method of treating idiopathic inflammatory myopathy in an individual is described. The method involves administering an effective amount of umbilical lining-derived stem cells to the individual. The method may involve reducing or tapering steroid usage in individual afflicted with idiopathic inflammatory myopathy. The method may involve administering a single dose of the umbilical lining-derived stem cells, or administering multiple doses of the umbilical lining-derived stem cells over a defined period of time.

The invention belongs to the technical field of molecular diagnosis and immunotherapy, and particularly relates to a group of biomarkers and application thereof in diagnosis of immune-mediated necrotizing myopathy. The invention firstly provides a group of biomarkers for predicting, treating or diagnosing immune-mediated necrotizing myopathy, and the biomarkers are protein markers, and comprise one or a combination of more than two markers selected from CSRP3, HSP90AB1, MYH1, ITGB1BP2, SMPX, MYBPC2, CD9, ICAM1, ANKRD1 and NT5C1A. The invention also provides application of the marker in preparation of a product for predicting, treating or diagnosing immune-mediated necrotizing myopathy. Through muscle proteomics analysis, a unique and shared way in anti-SRP and anti-HMGCR myopathy is disclosed, and it is determined that HSP90AB1, ITGB1BP2, CD9, ICAM1 and ANKRD1 are potential biomarkers for the severity of IMNM diseases. These findings provide valuable insights for the determination of pathogenesis and therapeutic targets of IMNM.

This invention provides a method and apparatus for predicting the progression of myopathy based on spatiotemporal topological networks. First, muscle biopsy sections from multiple time points of the patient are segmented and quantized to construct a static pathological topological network with individual muscle fibers as nodes and spatial adjacency relationships as edges. Nodes contain multidimensional features such as subtype, morphology, texture, and cell nucleus, and are arranged chronologically to form spatiotemporal graph data. This data is input into a pre-trained spatiotemporal graph neural network. Its spatial encoding layer aggregates neighborhood information through a graph convolutional network to capture spatial interactions, its temporal encoding layer learns temporal evolution patterns through a recurrent neural network, and its decoding layer predicts the network state at the next time point. Through iterative prediction, pathological network sequences at multiple future time points are generated. Key indicators are then extracted to plot quantitative prediction curves and generate a visualized pathological heatmap, achieving a leap from static pathology to dynamic progression, providing an objective and accurate tool for clinical prognostic assessment of myopathy.

The present invention provides a hardware-friendly framework for implementing a point-of-care diagnosis hardware tool for practical end-user convenience, power saving and resource utilization. The hardware tool is non-invasive and comfortable for the patient, as a primary means of differential diagnosis between two neuromuscular diseases such as neuropathy and myopathy. The provided hard-ware tool comprises a feature extractor configured to receive electrodiagnostic signals (preferably EMG signals) of a patient and extract one or more features from the collected signals; and a classifier configured to receive the extracted features and classify a neuromuscular disease for the patient based on the extracted features. The classifier is a single layer machine-learning perceptron trained with datasets consisted of electrodiagnostic signals of patients to perform a linearly separable binary classification.

The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods of treating neuromuscular inflammatory indications, such as Immune-Mediated Necrotizing Myopathy.

The invention relates to the technical field of atrial fibrillation recognition, in particular to an artificial intelligence atrial fibrillation recognition system based on an MRI image, computer equipment and a storage medium, and the method comprises the steps: inputting an MRI-DWI image sequence collected at the early stage of admission of a stroke patient; performing standardized preprocessing on the image; entering a double-branch architecture of an AI model, and extracting semantic features of a stroke focus area; meanwhile, multi-dimensional image omics features are extracted from the focus area; the semantic features and the multi-dimensional image omics features are fused, and an AF classification result is output through a full connection layer Softmax; in the training stage, Dice loss and a cross entropy loss function are used for joint optimization, and in the testing stage, an AF prediction probability is output. The method can be expanded to other high-risk screening fields of cardiac stroke, atrial myopathy and the like through transfer learning. The system can also be integrated in a PACS system, automatic uploading, analysis and result pushing of images are achieved, and a clinical auxiliary basis is provided for a post-stroke anticoagulation strategy.

The present invention relates to: an M3 mutant peptide; a composition for alleviating, inhibiting, preventing or treating myopathy, obesity or diabetes, comprising same as an active ingredient; a method for alleviating, inhibiting, preventing or treating myopathy, obesity or diabetes by using the M3 mutant peptide; and uses of the M3 mutant peptide for alleviating, inhibiting, preventing or treating myopathy, obesity or diabetes.

The invention relates to a compound as shown in a formula I and application of the compound as an S1PR regulator, in particular to application of a selective S1PR4 agonist in myopathy treatment. The compound can be used for treating related diseases mediated by S1PR4 and a mutant thereof.

The present invention relates to methods for obtaining an expanded population of skeletal muscle derived cells (SMDC). The present invention also refers to an expanded population of SMDCs obtained by the method according to the present invention and to an expanded population of SMDCs. Further, the present invention refers to an expanded population of SMDCs for use in a method for treatment of the human or animal body by surgery or therapy or for use as a pharmaceutical composition. In addition, the present invention refers to an expanded population of SMDCs for use in a method of preventing and / or treating neuromyopathies, myopathies and / or muscle dysfunctions such as a urinary and / or an anal incontinence.